
    
      Patient is randomized to receive investigational product or placebo at week 0 and week 4
      (1:1)

        -  arm 1: 2 infusions four weeks apart of tocilizumab 8mg/kg

        -  arm 2: 2 infusions four weeks apart of saline solution

      Follow-up visits are organized at week 6, and then week 8 and week 12.

      Primary outcome is the pain as assessed with the VAS at week 6. Secondary outcomes include
      morning stiffness duration, patient and practitioner global assessments, functional indexes
      for hand OA, number of painful joints, number of swollen joints.

      110 patients is expected to be randomized in 36 months. Each patient sign an informed consent
      before the beginning of the study.
    
  